Think of the Neurokinin-1 Antagonists as Equally Efficacious

Rolapitant (Varubi) will compete with older neurokinin-1 antagonists to prevent chemotherapy-induced nausea and vomiting.

It will join oral aprepitant and IV fosaprepitant (Emend, etc) and the combo of netupitant and the 5-HT3 antagonist palonosetron (Akynzeo).

We know that highly emetogenic chemotherapy (cisplatin, etc) requires using a three-drug regimen of a neurokinin-1 (NK-1) antagonist... 5-HT3 antagonist (ondansetron, etc)...and dexamethasone.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals